Bimagrumab is a human monoclonal antibody that binds type II activin receptors (ActRII), blocking the binding of myostatin and activin and the signaling that follows. It is being studied in obesity and overweight.
Summary written with AI from the sources listed at the end of this page.
At a glance
Also known as
LY3985863, BYM-338, VER201
Drug type
Monoclonal antibody
Targets
Type II activin receptor (ActRII/ACVR2) (ACVR2A)
Mechanism
Antagonist of Type II activin receptor (ActRII/ACVR2) (ACVR2A)
Pathways
ActRII-mediated signaling, protein synthesis, protein degradation, skeletal muscle cell growth
Data: FDA (Drugs@FDA, Purple Book, DailyMed), NIH (NCI Thesaurus, GSRS, RxNorm), ClinicalTrials.gov • Informational purposes only, not medical or investment advice. • All drugs A–Z
This data is for informational purposes only, not investment advice. BioRadar does not provide buy/sell recommendations. Past performance does not guarantee future results. Always do your own due diligence.